Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $19 | $19 | $13 |
| G&A Expenses | $5 | $6 | $7 | $6 |
| SG&A Expenses | $5 | $6 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $4 | $0 | $0 |
| Operating Expenses | $15 | $29 | $26 | $19 |
| Operating Income | -$16 | -$29 | -$26 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | -$5 | $5 |
| Pre-Tax Income | -$15 | -$29 | -$31 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$29 | -$31 | -$14 |
| % Margin | – | – | – | – |
| EPS | -0.73 | -1.56 | -2.31 | -0.54 |
| % Growth | 53.2% | 32.5% | -327.8% | – |
| EPS Diluted | -0.73 | -1.56 | -2.31 | -0.54 |
| Weighted Avg Shares Out | 21 | 19 | 18 | 18 |
| Weighted Avg Shares Out Dil | 21 | 19 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $5 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$14 | -$28 | -$25 | -$19 |
| % Margin | – | – | – | – |